The Role of BCMA-Directed Therapy in Relapsed Refractory Multiple Myeloma (R/R MM)

Sagar Lonial, MD, FACP, provides an overview of the potential treatment options for patients with relapsed/refractory multiple myeloma.

Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.

A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.

Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.

Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.

The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, reviews the design and outcomes of the DREAMM-2 and ALGONQUIN studies investigating belantamab mafodotin in the treatment of relapsed/refractory multiple myeloma.

Hana Safah, MD, presents the case of a 63-year-old woman with relapsed/refractory multiple myeloma receiving treatment with a BCMA-directed CAR T-cell therapy.

Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.

Drs Krina Patel and Hana Safah explain their impressions of the data on BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma and its potential impact on clinical practice.

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.